Piper Jaffray Companies Reiterates $120.00 Price Target for BioMarin Pharmaceutical (NASDAQ:BMRN)

Share on StockTwits

BioMarin Pharmaceutical (NASDAQ:BMRN) has been assigned a $120.00 target price by equities researchers at Piper Jaffray Companies in a research report issued to clients and investors on Friday, TipRanks reports. The firm presently has a “buy” rating on the biotechnology company’s stock. Piper Jaffray Companies’ price objective points to a potential upside of 65.18% from the company’s current price.

A number of other research analysts also recently issued reports on the company. JPMorgan Chase & Co. restated a “buy” rating and set a $133.00 price target on shares of BioMarin Pharmaceutical in a research note on Monday, August 5th. Citigroup restated a “buy” rating on shares of BioMarin Pharmaceutical in a research note on Thursday, May 23rd. Wedbush restated an “outperform” rating and set a $128.00 price target on shares of BioMarin Pharmaceutical in a research note on Wednesday, July 10th. BidaskClub downgraded BioMarin Pharmaceutical from a “sell” rating to a “strong sell” rating in a research note on Friday, July 26th. Finally, Stifel Nicolaus set a $108.00 price target on BioMarin Pharmaceutical and gave the stock a “buy” rating in a research note on Friday. Two analysts have rated the stock with a sell rating, four have issued a hold rating and thirteen have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $115.33.

NASDAQ:BMRN traded down $0.15 during mid-day trading on Friday, reaching $72.65. 966,431 shares of the stock were exchanged, compared to its average volume of 991,765. The company has a 50 day simple moving average of $76.00 and a 200-day simple moving average of $83.87. The stock has a market capitalization of $13.06 billion, a P/E ratio of -220.15 and a beta of 1.32. The company has a quick ratio of 2.79, a current ratio of 4.11 and a debt-to-equity ratio of 0.28. BioMarin Pharmaceutical has a 1 year low of $70.82 and a 1 year high of $106.74.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings results on Thursday, August 1st. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.16). The firm had revenue of $388.00 million for the quarter, compared to analysts’ expectations of $415.03 million. BioMarin Pharmaceutical had a negative return on equity of 3.12% and a negative net margin of 7.19%. The company’s quarterly revenue was up 4.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.09) EPS. As a group, research analysts predict that BioMarin Pharmaceutical will post -0.03 EPS for the current year.

In other BioMarin Pharmaceutical news, Director V Bryan Lawlis sold 3,750 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Monday, June 17th. The stock was sold at an average price of $81.08, for a total value of $304,050.00. Following the transaction, the director now directly owns 27,340 shares in the company, valued at approximately $2,216,727.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 1.90% of the company’s stock.

Several institutional investors have recently bought and sold shares of BMRN. Comerica Securities Inc. boosted its stake in shares of BioMarin Pharmaceutical by 23.9% in the fourth quarter. Comerica Securities Inc. now owns 3,197 shares of the biotechnology company’s stock valued at $272,000 after buying an additional 617 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of BioMarin Pharmaceutical by 6.0% in the fourth quarter. Geode Capital Management LLC now owns 1,643,507 shares of the biotechnology company’s stock valued at $139,844,000 after buying an additional 92,519 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of BioMarin Pharmaceutical by 7.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 309,779 shares of the biotechnology company’s stock valued at $26,375,000 after buying an additional 21,009 shares in the last quarter. Janney Montgomery Scott LLC boosted its stake in shares of BioMarin Pharmaceutical by 4.0% in the first quarter. Janney Montgomery Scott LLC now owns 6,940 shares of the biotechnology company’s stock valued at $616,000 after buying an additional 268 shares in the last quarter. Finally, Janus Henderson Group PLC boosted its stake in shares of BioMarin Pharmaceutical by 1.8% in the first quarter. Janus Henderson Group PLC now owns 45,660 shares of the biotechnology company’s stock valued at $4,054,000 after buying an additional 812 shares in the last quarter. Hedge funds and other institutional investors own 98.08% of the company’s stock.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

Featured Story: Buyback

Analyst Recommendations for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Invesco Ltd. Buys New Position in Anterix Inc
Invesco Ltd. Buys New Position in Anterix Inc
180 Wealth Advisors LLC Makes New Investment in CenterPoint Energy, Inc.
180 Wealth Advisors LLC Makes New Investment in CenterPoint Energy, Inc.
iShares MSCI Eurozone ETF  Shares Acquired by Envestnet Asset Management Inc.
iShares MSCI Eurozone ETF Shares Acquired by Envestnet Asset Management Inc.
GRIFOLS S A/S  Shares Purchased by Envestnet Asset Management Inc.
GRIFOLS S A/S Shares Purchased by Envestnet Asset Management Inc.
Commerzbank Aktiengesellschaft FI Sells 8,726 Shares of Tc Pipelines Lp
Commerzbank Aktiengesellschaft FI Sells 8,726 Shares of Tc Pipelines Lp
Commerzbank Aktiengesellschaft FI Decreases Stake in Cognizant Technology Solutions Corp
Commerzbank Aktiengesellschaft FI Decreases Stake in Cognizant Technology Solutions Corp


 
© 2006-2019 Zolmax.